Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

EMA picks projects for adaptive licensing project

Begins discussions on how the model will be implemented in practice

Astellas forges $675m muscle alliance with Cytokinetics

Extendscollaboration to include neuromuscular diseases

NICE rejection of three ovarian cancer drugs stands

Agency will still not recommend Gemzar, Hycamtin and Yondelis for the disease

- PMLiVE

Media planning on a global scale

Think international when combining the most appropriate media vehicles and formats for marketing efforts

- PMLiVE

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

Bone Therapeutics looks to Pfizer for clinical head

Guy Heynen has 35 years of industry experience

- PMLiVE

BioCryst gets FDA nod for first intravenous flu drug

Expects to launch Rapivab in time for this year's flu season

- PMLiVE

EU approval for Lilly’s Cyramza in stomach cancer

Follows shortly after the drug's US approval in non-small cell lung cancer

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

- PMLiVE

FDA backs Cubist’s antibiotic Zerbaxa

Combination cephalosporin and beta lactamase inhibitor wins US approval

The impending threat of antibiotic resistance

Antibiotic Research UK is the BIA's charity of 2015, but what does it intend to do?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links